Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 4/20 | 0.54 |
| ▸ | BCHE | P06276 | 1/20 | 0.53 |
| ▸ | HTR1A | P08908 | 2/20 | 0.52 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | HTR1D | P28221 | 1/20 | 0.52 |
| ▸ | HTR1B | P28222 | 1/20 | 0.52 |
| ▸ | HTR2C | P28335 | 1/20 | 0.52 |
| ▸ | HTR1E | P28566 | 1/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.52 |
| ▸ | HTR7 | P34969 | 1/20 | 0.52 |
| ▸ | HTR2B | P41595 | 1/20 | 0.52 |
| ▸ | HTR6 | P50406 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
| ▸ | CTSL | P07711 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6024202 | 1.00 | HTR2A (0.54) | HTR2ABCHEHTR1AADRB1ADRA2A | |
| Hydrochloric Acid SCHEMBL2490437 | 0.99 | HTR2A (0.52) | HTR2ABCHEHTR1AADRB1ADRA2A | |
| Hydrochloric Acid SCHEMBL6024099 | 0.99 | HTR2A (0.52) | HTR2ABCHEHTR1AADRB1ADRA2A | |
| SCHEMBL23679540 | 0.86 | HTR2A (0.56) | HTR2AHTR1AADRB1ADRA2ASLC6A2 | |
| SCHEMBL6023654 | 0.82 | HTR1B (0.41) | BCHEHTR1AADRB1HTR1DHTR1B | |
| SCHEMBL26084484 | 0.82 | HTR2A (0.55) | HTR2AHTR1AADRB1ADRA2ASLC6A2 | |
| Hydrochloric Acid SCHEMBL6023966 | 0.81 | HTR1B (0.40) | BCHEHTR1AADRB1HTR1DHTR1B | |
| SCHEMBL28271507 | 0.81 | BCHE (0.59) | HTR2ABCHEHTR1AADRB1ADRA2A | |
| SCHEMBL28273031 | 0.81 | BCHE (0.59) | HTR2ABCHEHTR1AADRB1ADRA2A | |
| SCHEMBL28271495 | 0.81 | BCHE (0.59) | HTR2ABCHEHTR1AADRB1ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3226852-B1 | ARYLALKYLAMINE COMPOUNDS FOR USE IN THE PREVENTION OR TREATMENT OF CANCER | SEMMELWEIS UNIV (HU) | 2020-03-18 | — | — | EP | claimed |
| US-10258599-B2 | Compounds for use in the prevention or treatment of cancer | SEMMELWEIS UNIVERSITY (HU) | 2019-04-16 | — | — | US | claimed |
| US-20170319535-A1 | COMPOUNDS FOR USE IN THE PREVENTION OR TREATMENT OF CANCER | SEMMELWEIS UNIVERSITY (HU) | 2017-11-09 | — | — | US | claimed |
| EP-3226852-A1 | ARYLALKYLAMINE COMPOUNDS FOR USE IN THE PREVENTION OR TREATMENT OF CANCER | Semmelweis University (HU) | 2017-10-11 | — | — | EP | claimed |
| CN-107205965-A | For prevention or the aralkylamine compound for the treatment of cancer | 森梅威思大学 | 2017-09-26 | — | — | CN | claimed |
| WO-2016088112-A1 | ARYLALKYLAMINE COMPOUNDS FOR USE IN THE PREVENTION OR TREATMENT OF CANCER | SEMMELWEIS UNIVERSITY (HU) | 2016-06-09 | — | — | WO | claimed |
| CN-107205965-B | Arylalkyl amine compounds for preventing or treating cancer | 森梅威思大学 | 2020-10-27 | — | — | CN | disclosed |
| EP-3226852-B1 | ARYLALKYLAMINE COMPOUNDS FOR USE IN THE PREVENTION OR TREATMENT OF CANCER | SEMMELWEIS UNIV (HU) | 2020-03-18 | — | — | EP | disclosed |
| US-10258599-B2 | Compounds for use in the prevention or treatment of cancer | SEMMELWEIS UNIVERSITY (HU) | 2019-04-16 | — | — | US | disclosed |
| US-20170319535-A1 | COMPOUNDS FOR USE IN THE PREVENTION OR TREATMENT OF CANCER | SEMMELWEIS UNIVERSITY (HU) | 2017-11-09 | — | — | US | disclosed |
| US-20170319535-A1 | COMPOUNDS FOR USE IN THE PREVENTION OR TREATMENT OF CANCER | SEMMELWEIS UNIVERSITY (HU) | 2017-11-09 | — | — | US | disclosed |
| EP-3226852-A1 | ARYLALKYLAMINE COMPOUNDS FOR USE IN THE PREVENTION OR TREATMENT OF CANCER | Semmelweis University (HU) | 2017-10-11 | — | — | EP | disclosed |
| WO-2016088112-A1 | ARYLALKYLAMINE COMPOUNDS FOR USE IN THE PREVENTION OR TREATMENT OF CANCER | SEMMELWEIS UNIVERSITY (HU) | 2016-06-09 | — | — | WO | disclosed |
| US-8178686-B2 | Process for preparing optically active aminopentane derivative, intermediate and process for preparing intermediate | FUJIMOTO CO., LTD. (JP) | 2012-05-15 | — | — | US | disclosed |
| EP-1905760-B1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE AMINOPENTANE DERIVATIVE, INTERMEDIATE IN THE PROCESS AND PROCESS FOR PRODUCTION OF THE INTERMEDIATE | FUJIMOTO CO LTD (JP) | 2011-10-26 | — | — | EP | disclosed |
| US-20100324300-A1 | PROCESS FOR PREPARING OPTICALLY ACTIVE AMINOPENTANE DERIVATIVE, INTERMEDIATE AND PROCESS FOR PREPARING INTERMEDIATE | YONEDA FUMIO | 2010-12-23 | — | — | US | disclosed |
| US-7807840-B2 | Process for preparing optically active aminopentane derivative, intermediate and process for preparing intermediate | FUJIMOTO CO., LTD. (JP) | 2010-10-05 | — | — | US | disclosed |
| US-20090124813-A1 | Process for Preparing Optically Active Aminopentane Derivative, Intermediate and Process for Preparing Intermediate | FUJIMOTO CO., LTD. (JP) | 2009-05-14 | — | — | US | disclosed |
| EP-1905760-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE AMINOPENTANE DERIVATIVE, INTERMEDIATE IN THE PROCESS AND PROCESS FOR PRODUCTION OF THE INTERMEDIATE | Fujimoto Co., Ltd. (JP) | 2008-04-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124813-A1 | Process for Preparing Optically Active Aminopentane Derivative, Intermediate and Process for Preparing Intermediate | API5, CASP5, BAD | HTR2A 96/4885BCHE 246/4885HTR1A 42/4885 |
| US-10258599-B2 | Compounds for use in the prevention or treatment of cancer | TMSB10, PNMT, HNMT | HTR2A 590/4885BCHE 516/4885HTR1A 607/4885 |
| US-20170319535-A1 | COMPOUNDS FOR USE IN THE PREVENTION OR TREATMENT OF CANCER | TMSB10, PNMT, HNMT | HTR2A 603/4885BCHE 499/4885HTR1A 590/4885 |
| US-20100324300-A1 | PROCESS FOR PREPARING OPTICALLY ACTIVE AMINOPENTANE DERIVATIVE, INTERMEDIATE AND PROCESS FOR PREPARING INTERMEDIATE | API5, CASP5, BAD | HTR2A 96/4885BCHE 246/4885HTR1A 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.